US President Donald Trump has signed an executive order that could impose tariffs of up to 100% on certain imported patented medicines from companies that do not reach agreements with his administration in the coming months, according to Bloomberg [1]. The new tariffs will apply to patented drugs manufactured in countries without tariff deals with the US, specifically targeting companies that lack most-favored-nation-pricing agreements with the administration [1]. Duties for products made by larger companies will take effect in 120 days, while items from smaller manufacturers will not be subject to tariffs for another 180 days [1].
Trump's move comes amid the run-up to the November 2024 presidential election, with the stated intention of using tariffs to support the US economy and American producers [1]. In 2024, Mexico, China, and Canada accounted for 42% of total US imports, with Mexico being the top exporter at $466.6 billion, according to the US Census Bureau [1]. Trump aims to focus on these three nations when imposing tariffs and plans to use the revenue generated from these tariffs to lower personal income taxes [1].
Economists are divided on the impact of tariffs. Some argue that tariffs are necessary to protect domestic industries and address trade imbalances, while others warn that such measures could drive prices higher over the long term and potentially lead to a damaging trade war through retaliatory tariffs [1].
No specific market reactions or analyst opinions were provided in the article, and there were no mentions of particular pharmaceutical companies or ticker symbols [1].
CONCLUSION
President Trump's executive order to impose up to 100% tariffs on certain patented drug imports is expected to have a significant impact on international trade and the pharmaceutical sector. The move is intended to bolster the US economy and reduce personal income taxes, but economists remain divided on its long-term effects. The lack of immediate market reaction or analyst commentary leaves uncertainty about the broader implications for drug prices and trade relations.